EUVIMEDEUVIMED entdecken
Crossref

Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis

Qiang Su, Qiuhong Yao, Tinghui Yue, Run Shi, Yuhao Xie, Chuang Liu, Jiang Liang, Yuanli He, Zhenxiang An

Phytomedicine · 2026-09 · 159 · 158554

DOI: 10.1016/j.phymed.2026.158554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-09. Verfasst von Qiang Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China; Department of Gastroenterology, First Affilia…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Colitis, Ulcerative, Receptors, Aryl Hydrocarbon, Plant Extracts. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ulcerative colitis (UC) poses a therapeutic challenge due to persistent epithelial barrier dysfunction. The traditional Miao medicine Osbeckia opipara (O. opipara) shows clinical efficacy, yet its mechanism remains unclear. PURPOSE: To elucidate the therapeutic mechanism of O. opipara in UC through integrated pharmacological and experimental approaches. STUDY DESIGN: A bedside to bench translational framework was employed combining multiomics analysis, genetic causal inference, molecular simulation and experimental validation in preclinical models. METHODS: Active constituents were characterized using ultra high performance liquid chromatography tandem mass spectrometry. Drug target Mendelian randomization (DTMR) identified aryl hydrocarbon receptor (AHR) and signal transducer and activator of transcription 3 (STAT3) as pivotal genetic targets. Molecular dynamics simulations assessed ligand receptor interactions. Efficacy was evaluated in dextran sulfate sodium (DSS) induced colitis mice and lipopolysaccharide stimulated intestinal epithelial cells. Alterations in gut microbiota and host transcriptome were profiled by 16S ribosomal RNA sequencing and RNA sequencing respectively. RESULTS: O. opipara alleviated DSS-induced colitis, at least in part, through modulation of the AHR/IL-22/STAT3 signaling axis in preclinical models. Gallic acid and Ellagic acid were identified as core AHR agonists. Treatment significantly suppressed inflammatory responses, restored gut microbiota homeostasis, and reconstructed intestinal barrier integrity by upregulating tight junction proteins. AHR inhibition abolished these therapeutic effects, confirming the mechanism's dependence on AHR activation. CONCLUSION: O. opipara acts as a natural AHR agonist that modulates inflammation, microbiota dysbiosis, and barrier dysfunction to promote mucosal healing in preclinical UC models, providing mechanistic evidence supporting its traditional therapeutic application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorColitis, UlcerativeReceptors, Aryl HydrocarbonPlant ExtractsAnimalsSignal TransductionMiceIntestinal Barrier FunctionInterleukin-22InterleukinsBasic Helix-Loop-Helix ProteinsMice, Inbred C57BLMaleIntestinal MucosaDextran SulfateDisease Models, AnimalHumansGastrointestinal MicrobiomeInflammation

Stichwörter der Autor:innen

AHRGut microbiotaIL-22Osbeckia opiparaSTAT3Ulcerative colitis

Substanzen

STAT3 Transcription FactorReceptors, Aryl HydrocarbonInterleukin-22InterleukinsBasic Helix-Loop-Helix ProteinsPlant ExtractsDextran SulfateStat3 protein, mouse

Autor:innen und Institutionen

  • The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China; Department of Gastroenterology, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Gu…
  • The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Pharmaceutical Sciences, St. John's University, Queens, NY, USA.
  • The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China; Department of Rheumatology and Hematology, First Affliated Hospital of Guizhou University of Traditional Chinese Me…
  • The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, China; Department of Cadre health care, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, G…

Zitieren

APA

Su, Q., Yao, Q., Yue, T., Shi, R., Xie, Y., Liu, C., Liang, J., He, Y., & An, Z. (2026). Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis. Phytomedicine, 159, 158554. https://doi.org/10.1016/j.phymed.2026.158554

Vancouver

Su Q, Yao Q, Yue T, Shi R, Xie Y, Liu C, et al. Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis. Phytomedicine. 2026;159:158554. doi:10.1016/j.phymed.2026.158554

BibTeX
@article{Su2026,
  author = {Su, Qiang and Yao, Qiuhong and Yue, Tinghui and Shi, Run and Xie, Yuhao and Liu, Chuang and Liang, Jiang and He, Yuanli and An, Zhenxiang},
  title = {Osbeckia opipara attenuates inflammation and reconstructs the intestinal barrier in ulcerative colitis by modulating the AHR/IL-22/STAT3 signaling axis},
  journal = {Phytomedicine},
  year = {2026},
  volume = {159},
  pages = {158554},
  doi = {10.1016/j.phymed.2026.158554}
}
Kostenlos starten →